TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00625612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denufosol Tetrasodium (INS37217) Inhalation Solution
Description: Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
Study: NCT03185793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzbromarone
Description: 25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
Study: NCT05019859

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low carb diet
Description: low carb diet
Study: NCT00625612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
Study: NCT03097497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy re-education program
Description: Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
Study: NCT03690180

Intervention type: DIAGNOSTIC_TEST
Intervention: serum magnesium
Description: assessment of serum magnesium in all patients

Intervention type: DIAGNOSTIC_TEST
Intervention: serum magnesium
Description: assessment of serum magnesium in all patients
Study: NCT01075971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
Description: 8 mg or 16 mg daily, sublingual route on Days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine hydrochloride fast dissolving tablet (FDT)
Description: 8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
Study: NCT02576860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001 (Omiganan)
Description: Topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle gel
Study: NCT02146677

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic manipulative treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Sham therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study: NCT03097497

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment by GP
Description: Patients will follow the general practitioner's advice including medication if needed
Study: NCT02146677

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study: NCT02606227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Vouchers

Intervention type: OTHER
Group type: OTHER
Intervention: No financial incentive
Description: No financial intervention
Study: NCT04947306

Intervention type: DEVICE
Intervention: Tetragraph® (Senzime, Uppsala, Sweden)
Description: The Tetragraph® is a recently marketed electromyographic neuromuscular monitor that uses a disposable electrode array (TetraSens) that combines stimulating and recording electrodes

Intervention type: DEVICE
Intervention: TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)
Description: The TOF Watch® SX is a common used neuromuscular monitor
Study: NCT01388751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: night splinting
Description: splint finger at night for 4 weeks
Study: NCT02358044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron
Description: PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazoprevir/Elbasvir (100 mg/50 mg) FDC
Description: Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
Study: NCT01636713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/VI 62.5/25
Description: Inhalation via Novel Dry Powder Inhaler Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/VI 125/25
Description: Inhalation via Novel Dry Powder Inhaler Once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Study: NCT03780959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered twice weekly by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Administered twice weekly by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice weekly by subcutaneous injection
Study: NCT04493684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (PIB)
Description: GSK3739937 will be administered as oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (Tablet)
Description: GSK3739937 Tablet will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (Tablet)
Description: GSK3739937 Tablet will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3739937 (Tablet)
Description: GSK3739937 Tablet will be administered via oral route.
Study: NCT03202108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krio
Description: Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian.
Study: NCT04639817

Intervention type: DRUG
Intervention: Levofloxacin
Description: Levofloxacin administration

Intervention type: DRUG
Intervention: trimethoprim-sulfamethoxazole
Description: Trimethoprim-sulfamethoxazole administration
Study: NCT03283436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 0.25% Injection Solution
Description: 10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
Study: NCT00221975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Divalproex
Description: Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
Study: NCT03220607

Intervention type: OTHER
Intervention: uterocervical angle
Description: uterocervical angle is the angle between lower segment of uterus and cervix
Study: NCT03697993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine
Description: Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
Study: NCT02983591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol after delivery
Description: Patients will receive 1000 mcg Misoprostol per rectum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin after delivery
Description: Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin before delivery
Description: All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin before delivery
Description: All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
Study: NCT03823872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Time restricted feeding= consume food only from 12:00pm-8:00pm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Time restricted feeding= consume food only from 12:00pm-8:00pm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal feeding
Description: Normal feeding= consume food per normal schedule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal feeding
Description: Normal feeding= consume food per normal schedule
Study: NCT02423122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-745
Description: Orally-Active Selective P45 MAP Kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-745
Description: Orally-Active Selective P45 MAP Kinase inhibitor
Study: NCT02449018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: QBW251 capsule(s) taken orally twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule(s) taken orally twice per day
Study: NCT03645317

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood tests & cardiac imaging
Description: Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
Study: NCT00801060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumiliximab + FCR
Description: Dose, schedule, and duration in the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCR
Description: Dosage, schedule, and duration in the protocol
Study: NCT00860015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: 500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy.
Study: NCT04276688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: 400mg/100mg twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: 400mg/100mg twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 400mg twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1B
Description: 0.25mg subcutaneous injection alternate day for 3 days
Study: NCT03371953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium
Description: A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium + Atracurium
Description: A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
Study: NCT02288013

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Closure of uterine incision at C section
Description: Closure of uterine incision at Cesarean section

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Closure of uterine incision at C section
Description: Closure of uterine incision at Cesarean section
Study: NCT03340194

Intervention type: RADIATION
Intervention: Radiography
Description: Radiography of the hand and feet (face incident) the day of the inclusion

Intervention type: PROCEDURE
Intervention: Veinous punction
Description: Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
Study: NCT03817294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of exercise training modalities
Description: As above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of exercise training modalities
Description: As above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of exercise training modalities
Description: As above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of exercise training modalities
Description: As above
Study: NCT01972698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-directed and simulation-assisted training
Description: All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~* A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~* Participant will have access to an ultrasound simulator.~* Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional apprenticeship training
Description: All participants will attend an half-day ultrasound introductory course.~* Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~* Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer.
Study: NCT02871687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
Study: NCT03989999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD)
Description: In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury.~If TCD is normal (FVd\>25 cm/sec and PI \<1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (\< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group.
Study: NCT04208399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 will be administered orally in fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 will be administered orally in fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 will be administered orally in fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 will be administered orally in fed condition.
Study: NCT04990414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.
Study: NCT01349062

Intervention type: DRUG
Group type: OTHER
Intervention: Kallunk oxide (Immunotherapy) 
Description: The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum.
Study: NCT02287753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vascular occlusion test using Pediatric SomaSensor for INVOS 5100C
Description: Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.